Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.
A recent study revealed a 17.5% increase in asthma-related hospitalizations in the three months following the announcement that GSK would discontinue the widely used asthma medication Flovent, and ...
Tezspire's 2021 approval in severe asthma represents a rapidly growing biologic market opportunity of over $7.5 billion. Early preclinical and clinical data for verekitug indicate a potential for ...